Loading...
NPI 1134377781 · Huntsville, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Eurofins Diatherix Laboratories LLC is a clinical medical laboratory provider located in Huntsville, Alabama. This profile covers 19 Medicare and 35 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Eurofins Diatherix Laboratories LLC |
| Address | 601 Genome Way |
| City | Huntsville |
| State | AL |
| ZIP | 35806 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 8, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $145.1M |
| Medicare | $80.6K |
EUROFINS DIATHERIX LABORATORIES LLC reports $80.6K in lifetime Medicare revenue versus $145.1M in lifetime Medicaid revenue, indicating Medicaid overwhelmingly drives this provider’s billing footprint. The NPI was enumerated on 2008-09-08 (~18 years ago), showing an established presence while the business is effectively single-payer in scale given the huge Medicaid concentration relative to Medicare.
The provider’s code mix and highest-dollar Medicaid codes indicate a centralized, high-throughput molecular diagnostics operation focused on respiratory and infectious-agent testing. Medicaid top codes include 87633 (535.4K claims, $51.9M revenue, 35.8% of Medicaid revenue), U0003 (596K claims, $33.4M revenue, 23.0% of Medicaid revenue), and 87798 (588.1K claims, $9.4M revenue, 6.5% of Medicaid revenue), which together reflect multiplex respiratory panels and SARS-CoV-2 nucleic acid testing as core services.
Revenue concentration is pronounced for both payers: the top three Medicare codes account for 38.1% of this provider’s total Medicare revenue, while the top three Medicaid codes account for 65.4% of total Medicaid revenue. This concentration suggests business results are highly sensitive to utilization and reimbursement across a small set of high-volume infectious-disease and respiratory test codes.
Across Medicaid the practice is a dominant state-level performer on its flagship tests: 87633 ranks #1 of 98 providers in-state (100th percentile; extreme outlier, far above typical state volume for this code), U0003 ranks #1 of 65 providers in-state (100th percentile; extreme outlier), and multiple other high-volume codes also rank #1 or in the top few in-state (many labeled extreme outlier). These statewide ranks indicate the provider is a primary destination for Medicaid infectious-disease testing in Alabama.
Medicare billing is modest in scale and shows mostly typical national volumes for the same molecular diagnostics mix. For Medicare, U0003 generated $11.8K (14.8% of Medicare revenue) and ranks #394 of 973 providers nationally (59th percentile; typical, unremarkable volume), while 87486 ($9.6K; 12.0%) and 87798 ($9K; 11.3%) likewise show mostly middle-percentile national ranks; collectively this points to a limited national Medicare footprint despite extensive Medicaid activity.
While most Medicare codes are at typical national volumes, there are isolated Medicare percentiles that are relatively high for specific tests (for example, 87651 ranks #201 of 3530 providers nationally, 94th percentile), indicating pockets where the lab’s test mix achieves above-typical national participation. These pockets do not, however, materially change the overall picture that Medicare revenue is small in absolute terms compared with Medicaid.
The provider’s operational profile — very large claim counts on multiplex respiratory panels and SARS-CoV-2 NAATs (e.g., 535.4K claims for 87633 and 596K claims for U0003) — implies heavy reliance on scalable, automated molecular workflows and likely centralized specimen processing to support this volume. Given that several of these high-volume Medicaid codes are labeled “extreme outlier, far above typical state volume,” the lab’s capacity and throughput appear to be a critical competitive advantage in-state.
The concentration of revenue in a few high-volume infectious-disease codes combined with near-total dependence on Medicaid revenue creates specific business exposure: reimbursement changes or policy shifts affecting codes such as 87633, U0003, and 87798 could materially impact reported revenues. Conversely, the provider’s dominant in-state standing on those codes also suggests negotiating leverage and operational scale within the Alabama Medicaid market.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 160 | $70 | $11.8K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 330 | $30 | $9.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 300 | $30 | $9K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 280 | $30 | $8.1K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 30 | $290 | $7.6K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 260 | $30 | $7.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 220 | $30 | $6.4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 170 | $30 | $5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 160 | $30 | $4.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 150 | $30 | $3.7K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
35 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 535,390 | $100 | $51.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 595,950 | $60 | $33.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 588,110 | $20 | $9.4M |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 548,170 | $20 | $8.8M |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 65,790 | $100 | $6.8M |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 484,170 | $10 | $6.3M |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 196,560 | $20 | $3.9M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 97,610 | $40 | $3.9M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 290,990 | $10 | $3.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 162,150 | $20 | $3.1M |
Showing 1–10 of 35
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
35 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 60 | 1,260 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1 | 100 | 470 | $130 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 70 | 380 | $60 | $893.8K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 1 | 10 | 1,020 | $110 | $784.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 2 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 2 | 40 | 460 | $20 | $584.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 3 | 40 | 1,540 | $10 | $397.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 1 | 40 | 1,440 | $20 | $372.1K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 1 | 40 | 2,000 | $20 | $273.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1 | 30 | 1,190 | $30 | $272.8K |
Showing 1–10 of 35
Other providers in the same ZIP code as Eurofins Diatherix Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Debbie Redmond-hyder, Do, PC | AL | Pediatrics Physician | $0 | $1.3M |
| Optum Infusion Services 207 Inc | AL | Home Infusion Therapy Pharmacy | $0 | $1.3M |
| Heals Inc | AL | Pediatrics Physician | $0 | $1M |
| Tracy Schroeder Swartz | AL | Optometrist | $74.3K | $0 |
| Gregory Clardy | AL | Optometrist | $33.4K | $0 |
| Riley Barrett | AL | Physical Therapist | $23.3K | $0 |
| Blake Towe | AL | Clinical Social Worker | $10.2K | $0 |
| Treva Garcia | AL | Registered Dietitian | $2.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.